Papers in this category present clinical research that has a clear potential to optimize patient care, with particular emphasis on high quality randomized controlled trials, novel combination treatments, therapies, novel diagnostic or prognostic insights and new insights into mechanism of action.
Howard L. Kaufman, MD, FACS
“Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials”
Howard L. Kaufman, MD, FACS; Robert H. I. Andtbacka, MD, CM, FACS, FRCSC; Frances A. Collichio, MD; Michael Wolf, MS; Zhongyun Zhao, PhD; Mark Shilkrut, MD, PhD; Igor Puzanov, MD, MSCI, FACP and Merrick Ross, MD
Journal for ImmunoTherapy of Cancer 2017, 5:72 (19 September 2017)